Search | Chemistry World

Bespoke or bodged

30 April 2013 In the Pipeline

A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe

From lab to leader

2 April 2013 In the Pipeline

Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?

New antibiotics: what's the hold up?

6 March 2013 In the Pipeline

It’s more a research problem, than a commercial one, says Derek Lowe

Name reactions: how does the label stick?

25 January 2013 In the Pipeline

Derek Lowe investigates the long running tradition of naming reactions after their inventors

Fear of the unknown

2 January 2013 In the Pipeline

How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe

Full disclosure?

27 November 2012 In the Pipeline

The pharma industry should be more open with its trial data, says Derek Lowe

High finance meets big pharma?

31 October 2012 In the Pipeline

Derek Lowe examines an alternative funding model for pharmaceutical research

Under pressure

26 September 2012 In the Pipeline

There might be a better way to interview new starters, suggests Derek Lowe

Light in the lab

4 September 2012 In the Pipeline

Derek Lowe asks: Why don’t we use photochemistry more often?

Screen shots

26 July 2012 In the Pipeline

Derek Lowe makes the case against using 'frequent hitters' in your assays

A personnel question

21 June 2012 In the Pipeline

Derek Lowe would back a team of risk takers if he had to

Column: In the pipeline

28 March 2012 In the Pipeline

How long is 'too long' in the drug discovery game? Derek Lowe considers the effects of life in the lab

Column: In the pipeline

23 February 2012 In the Pipeline

Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love

Column: In the pipeline

27 January 2012 In the Pipeline

Derek Lowe wonders what the lab lingua franca might be in the years to come

Column: In the pipeline

22 December 2011 In the Pipeline

Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about

Column: In the pipeline

28 November 2011 In the Pipeline

Derek Lowes considers the perfect lab environment

Column: In the pipeline

26 October 2011 In the Pipeline

Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature

Column: In the pipeline

29 September 2011 In the Pipeline

You have to make space for good sense when thinking about safety, argues Derek Lowe

Column: In the pipeline

26 August 2011 In the Pipeline

Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal

Column: In the pipeline

28 July 2011 In the Pipeline

Derek Lowe highlights the less visible pitfalls on the road to a new drug

Column: In the pipeline

30 June 2011 In the Pipeline

The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?

Column: In the pipeline

31 May 2011 In the Pipeline

To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe

Column: In the pipeline

28 April 2011 In the Pipeline

The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country

Column: In the pipeline

30 March 2011 In the Pipeline

'Natural products are back!' is a headline Derek Lowe has seen several times before

Column: In the pipeline

24 February 2011 In the Pipeline

Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations

Column: In the pipeline

31 January 2011 In the Pipeline

Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential

Column: In the pipeline

5 January 2011 In the Pipeline

Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship

Column: In the pipeline

29 November 2010 In the Pipeline

Who's that asleep at the back? Don't be too quick to blame yourself when tedious talks and soporific seminars fail to inspire, says Derek Lowe

Column: In the pipeline

28 October 2010 In the Pipeline

Should companies focus on big markets and the blockbuster dream? The more modern approaches are not without risks, says Derek Lowe

Column: In the pipeline

28 September 2010 In the Pipeline

Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery

Column: In the pipeline

27 August 2010 In the Pipeline

Derek Lowe considers the quandaries of living in the age of the kinase

Column: In the pipeline

30 July 2010 In the Pipeline

Derek Lowe reminisces about lost laboratory techniques and wonders which will be next to go

Column: In the pipeline

25 June 2010 In the Pipeline

Derek Lowe ponders the possibility of phosphatase inhibitors

Column: In the pipeline

27 May 2010 In the Pipeline

Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be

Column: In the pipeline

28 April 2010 In the Pipeline

Derek Lowe wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale

Column: In the pipeline

31 March 2010 In the Pipeline

Derek Lowe waxes lyrical about the joys of the electronic lab notebook

Column: In the pipeline

26 February 2010 In the Pipeline

Derek Lowe takes a tour of the 'instrument graveyard'

Column: In the pipeline

28 January 2010 In the Pipeline

Derek Lowe wonders whether peer-reviewed papers or patents are more reliable

Column: In the pipeline

6 January 2010 In the Pipeline

Derek Lowe takes a look back over his 20 years as a medicinal chemist

Column: In the pipeline

26 November 2009 In the Pipeline

Is the pharmaceutical industry churning out copycat versions of existing therapies? Derek Lowe dispels a few myths about 'me-too' drugs

Column: In the pipeline

28 October 2009 In the Pipeline

Derek Lowe advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times

Column: In the pipeline

1 October 2009 In the Pipeline

Derek Lowe discusses the problem of leaning too heavily on favourite reactions

Column: In the pipeline

25 August 2009 In the Pipeline

Derek Lowe wonders why some diseases are easier to drug than others

Column: In the pipeline

28 July 2009 In the Pipeline

Derek Lowe considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder

Column: In the pipeline

26 June 2009 In the Pipeline

Derek Lowe wonders where we'd be without the formulation chemists

Column: In the pipeline

29 May 2009 In the Pipeline

Derek Lowe wonders about pharmaceutical companies' motives for collaboration

Column: In the pipeline

28 April 2009 In the Pipeline

Derek Lowe considers what we think we know about how drugs work once we've taken them

Column: In the pipeline

30 March 2009 In the Pipeline

Derek Lowe considers the problems of addressing drug development out of sequence

Column: In the pipeline

23 February 2009 In the Pipeline

Derek Lowe worries that mergers are upsetting the balance of the pharmaceutical ecosystem

Column: In the pipeline

28 January 2009 In the Pipeline

How important is it to have the best equipped lab, wonders Derek Lowe

Column: In the pipeline

8 January 2009 In the Pipeline

Derek Lowe discusses the age-old tradition of passing the buck

Column: In the pipeline

27 November 2008 In the Pipeline

Derek Lowe ponders the likelihood of arriving where he started

Column: In the pipeline

29 October 2008 In the Pipeline

Testing times for Derek Lowe

Column: In the pipeline

26 September 2008 In the Pipeline

Derek Lowe seeks a cure for 'compound bloat'

Column: In the pipeline

27 August 2008 In the Pipeline

Derek Lowe remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'

How drugs get to market

27 August 2008 Review

Drug discovery and development

Column: In the pipeline

30 July 2008 In the Pipeline

Derek Lowe is looking for a little more variety among his reactions

Column: In the pipeline

30 June 2008 In the Pipeline

Derek Lowe says this is no time to be an 'ordinary' scientist

Column: In the pipeline

28 May 2008 In the Pipeline

Derek Lowe dreams of the day when chemists and biologists can understand each other

Column: In the pipeline

28 April 2008 In the Pipeline

Derek Lowe wonders what lessons we can learn from the Vytorin fiasco

Column: In the pipeline

26 March 2008 In the Pipeline

The recent row over antidepressants reminds us how little we know about the brain, says Derek Lowe

Column: In the pipeline

26 February 2008 In the Pipeline

Derek Lowe wonders how to revive some lost techniques

Column: In the pipeline

20 December 2007 In the Pipeline

It's been a rough year, but the future looks bright, says Derek Lowe

Column: In the pipeline

28 November 2007 In the Pipeline

Derek Lowe squares up to the challenge of biologics

Column: In the pipeline

26 October 2007 In the Pipeline

Chemists are finally going with the flow, says Derek Lowe

Column: In the pipeline

1 October 2007 In the Pipeline

The high cost of energy has an unexpected benefit, says Derek Lowe - it forces us to be more efficient

Column: In the pipeline

28 August 2007 In the Pipeline

Will Phase Zero trials actually help drug development, wonders Derek Lowe

Opinion: In the pipeline

26 July 2007 In the Pipeline

Process chemists just don't get the credit they deserve, says Derek Lowe

Opinion: In the pipeline

29 June 2007 In the Pipeline

The Avandia controversy poses some tough questions about how to balance risks, says Derek Lowe

Opinion: In the pipeline

24 May 2007 In the Pipeline

Derek Lowe sets the record straight about pharmaceutical patents on traditional medicines

Opinion: In the pipeline

27 April 2007 In the Pipeline

After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry, says Derek Lowe.

Opinion: In the pipeline

28 March 2007 In the Pipeline

Derek Lowe wonders whether total synthesis is still worth the effort

Opinion: In the pipeline

28 February 2007 In the Pipeline

Do the benefits of pharmaceutical company mergers really outweigh the costs, asks Derek Lowe

Opinion: In the pipeline

29 January 2007 In the Pipeline

Derek Lowe wonders whether the secret recipe for scientific breakthroughs can be taught - and how much indigestion that recipe would cause in the boardroom

Opinion: In the pipeline

20 December 2006 In the Pipeline

Derek Lowe looks at the recent failure of Pfizer's cholesterol drug, torcetrapib, and asks what it means for the future of pharmaceutical research

Opinion: In the pipeline

28 November 2006 In the Pipeline

Derek Lowe looks at the story behind the growing investment by western companies in medicinal chemistry research in China

Opinion: In the pipeline

30 October 2006 In the Pipeline

Derek Lowe wonders how to kill off bad drug candidates before companies invest valuable time and money in them

Search Results

Selected Filters

Filter Results